camizestrant (AZD9833)

Dr Erica Mayer (@elmayermd) is a co-investigator on SERENA-6 (NCT04964934), an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line treatment. Trial protocol: https://t.co/bIeMClWmjx (@DFCI_BreastOnc)

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line trea… https://t.co/kQji0I64pj Very nice ongoing study, reminiscent of the PADA 1 trial, but with a better (oral) SERD. I believe, however, that an arm is missing.... (@FilippoMontemu1)

New data supporting a deeper #ESR1 variant characterization in #BreastCancer. Y537S is resistant to #SERD #SERM due to stable conformation and activity. L536 shows varying sensitivity, greatest resistance: AZD9833 GDC-0810 RAD1901 #PrecisionMedicine #bcsm https://t.co/5llI1gngbs (@LGerratana)

Camizestrant Provides Survival Benefit Vs Fulvestrant in ER+/HER2- Advanced Breast Cancer https://t.co/eaFOVxaKCc via @onclive (@DrFaridSaleh)

Tumore della mammella ER+/HER2- avanzato, #camizestrant ritarda la progressione rispetto a fulvestrant. #SABCS22 https://t.co/KxFO4GNk2n (@PharmaStar)

内分泌療法既治療の進行ホルモン受容体陽性HER2陰性 #乳がん に、経口 #エストロゲン受容体分解薬（#SERD）である #camizestrant がフルベストラントよりも有効である可能性が明らかとなりました。今後の開発に期待します。 #SABCS22 https://t.co/w8tsIU5lvA (@cancer_navi)

SERENA-2: 1st head to head data of an oral SERD (Camizestrant) vs fulvestrant in a naive SERD population. ⬆️PFS with Camizestrant vs fulvestrant. Effect appears bigger in patients with prior CDK4/6i & ESR mutant breast cancers. These ph 2 data place Camizestrant on the map. (@cancermedic)

Congratulations @MOliveira_MD et al. for the great presentation at #SABCS22 of #SERENA2 trial on #camizestrant in pretreated patients with HR+/HER2- advanced #BreastCancer @SABCSSanAntonio @OncoAlert #bcsm (@matteolambe)

SERENA-2 . Camizestrant . New drug on the block . ESR1 mutation matters @SABCSSanAntonio #SABCS22 @DrSGraff @stolaney1 (@SuyogCancer)

Promise of SERDS being realized! Elacestrant VS ET of MD choice in preRx MBC in EMERALD improved PFS esp ESR1 mutated. Camizestrant > 3m PFS advantage over fulvestrant in 1/2nd line in SERENA-2, driven by ESR1 mt subset. Good news for MBC pts! #sabcs22 #bcsm (@DrLisaCarey)

SERENA-2 Results of camizestrant versus fulvestrant in patients with ER+/HER2- MBC. #SABCS22 (@drteplinsky)

Camizestrant improves PFS as compared to fulvestrant, regardless of prior CDK4/6, and among those with mutESR1. ⏭️Moving forward into phase 3 studies @OncoAlert #SABCS22 #SERENA2 (@DrSGraff)

#Camizestrant Oral SERD > IM #Fulvestrant for ER positive pts #breastcancer . 75mg dose seems ok. SERENA-2 trial nicely presented by @MOliveira_MD . Great we start seeing positive results with oral SERDs #SABCS22 @OncoAlert (@NagiSaghir)

SERENA-2: Camizestrant 75 mg or 150 mg vs fulvestrant in ER+ MBC presented by @MOliveira_MD demonstrating superiority (larger benefit in ESR1m) 37% w/ ESR1m 50% w/prior cdk 4/6i PFS: Cami 75 mg: 7.2 mo Cami 150 mg: 7.7 mo Fulvestrant: 3.7 mo @OncoAlert #SABCS22 #bcsm (@stolaney1)

Another piece of the puzzle: Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer. The oral SERDs saga continues. Stay tuned https://t.co/FwLjrGwOKG (@CarmenCriscit)

Excited to review the data at the upcoming meeting! Congrats to all involved. Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer | Business Wire https://t.co/Z1PhUWA5cb (@jhaveri_komal)

治療歴の多いER＋HER2－進行乳癌に対するAZD9833の単剤またはパルボシクリブとの併用は有望【SABCS2020】：がんナビ サンアントニオ乳がんシンポジウムからニュースを速報中です。 #乳がん #SABCS20 https://t.co/4BP6QGRbTy (@cancer_navi)

Agree these are metastatic highlights for #sabcs20. In posters - HER2: updated data on trastuzumab deruxtecan, tucatinib, neratinib & poziotinib. ER+: oral SERDs (AZD9833 +/- palbo) & followup data on alpelisib. TNBC: Sacituzumab govitecan & immune checkpoint inhibitor followup. (@jrgralow)